Details:
Candidate was discovered using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) and demonstrated potent and selective GPC3 binding, rapid cellular internalization and sustained tumor specific uptake and anti-tumor efficacy in pre-clinical models.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
Under the newly executed license agreement, Noile-Immune grants Chugai the rights to use PRIME technology for the creation and research of PRIME CAR-T cells, as well as the rights to develop, manufacture and commercialize PRIME CAR-T cell products, NIB102, for certain targets.
Lead Product(s): Nib-102
Therapeutic Area: Oncology Product Name: NIB102
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: $146.2 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 22, 2022
Details:
Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.
Lead Product(s): HTL0039732
Therapeutic Area: Oncology Product Name: HTL0039732
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 22, 2022
Details:
Takeda to acquire two clinical-stage compounds, sapanisertib (CB-228, formerly TAK-228) and mivavotinib (CB-659, formerly TAK-659), both of which have demonstrated single-agent clinical activity with the greatest potential in biomarker-defined cancerpatient populations.
Lead Product(s): Sapanisertib
Therapeutic Area: Oncology Product Name: CB-228
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Calithera Biosciences
Deal Size: $45.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition October 18, 2021
Details:
Chiome agreed to grant Henlius an exclusive right and license to antibodies targeting human TROP2 and related intellectual property rights to research, develop, manufacture and commercialize the Licensed Products in China.
Lead Product(s): LIV-2008
Therapeutic Area: Oncology Product Name: LIV-2008
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Henlius
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 14, 2021